While AI concept stocks are causing a stir on Wall Street and dominating headlines, companies in other sectors may offer qualities that high-growth AI firms lack: stability in turbulent markets. Healthcare giant Johnson & Johnson (JNJ) is a prime example. Over the past year, its stock price has quietly risen by 53%, outperforming most of the “Magnificent Seven” tech giants. However, after this rally, does this pharmaceutical behemoth still hold appeal? Let’s explore Johnson & Johnson’s investment potential for 2026.
Johnson & Johnson faces multiple challenges. First, several of its drugs have been included in government-led price negotiations, which could lead to a decline in sales of the related therapies. Second, there is the threat of a patent cliff. Last year, the company lost patent exclusivity for its immunology drug Stelara in the U.S., forcing it to compete with biosimilars. Additionally, sales of certain products have declined due to intense competition, such as the cancer drug Imbruvica. Finally, Johnson & Johnson still has to contend with thousands of lawsuits alleging that its talc-based products cause cancer.
Nevertheless, Johnson & Johnson demonstrates strong business resilience. Its core strength lies in a vast portfolio of drugs spanning multiple therapeutic areas, which ensures that despite competition from biosimilars and other factors, its overall sales and earnings can still maintain positive growth. Last year, despite declining revenues from drugs like Stelara and Imbruvica, the company still delivered impressive performance. Johnson & Johnson’s financial guidance for fiscal year 2026 also indicates a continuing positive outlook.
Diversification is another important buffer for Johnson & Johnson in dealing with price negotiations. Its medical devices division is set to launch robot-assisted surgical equipment, which is expected to create new growth opportunities. Moreover, the company boasts a robust balance sheet and the highest credit rating, demonstrating its ability to handle challenges posed by legal disputes.
For long-term income-focused investors, Johnson & Johnson is a high-quality income stock. The company has raised its dividend for 63 consecutive years, rightfully earning the title of “Dividend King.” In summary, despite facing short-term challenges, Johnson & Johnson’s diversified business structure, solid financial foundation, and consistent dividend growth record offer long-term investors a rare combination of safety and income. Among investment choices for 2026, this healthcare giant remains worthy of attention.
